CoChat
Sign Up
Cited by 671Inflammasome and immune disordersImmune Response and InflammationAutoimmune and Inflammatory Disorders Research

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Pharmacological Inhibitors of the NLRP3 Inflammasome

Open access
Zahid, Ayesha, Li, Bofeng, Kombe, Arnaud John Kombe, Jin, Tengchuan, Tao, Jinhui·2019·Frontiers in Immunology
DOI 10.3389/fimmu.2019.02538PMC PMC6842943
Open this paper in CoChat — free accountOpen PDF

Abstract

Inflammasomes play a crucial role in innate immunity by serving as signaling platforms which deal with a plethora of pathogenic products and cellular products associated with stress and damage. By far, the best studied and most characterized inflammasome is NLRP3 inflammasome, which consists of NLRP3 (nucleotide-binding domain leucine-rich repeat (NLR) and pyrin domain containing receptor 3), ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain), and procaspase-1. Activation of NLRP3 inflammasome is mediated by highly diverse stimuli. Upon activation, NLRP3 protein recruits the adapter ASC protein, which recruits the procaspase-1 resulting in its cleavage and activation, inducing the maturation and secretion of inflammatory cytokines and pyroptosis. However, aberrant activation of the NLRP3 inflammasome is implicated in various diseases including diabetes, atherosclerosis, metabolic syndrome, cardiovascular and neurodegenerative diseases; raising a tremendous clinical interest in exploring the potential inhibitors of NLRP3 inflammasome. Recent investigations have disclosed various inhibitors of the NLRP3 inflammasome pathway which were validated through in vitro studies and in vivo experiments in animal models of NLRP3-associated disorders. Some of these inhibitors directly target the NLRP3 protein whereas some are aimed at other components and products of the inflammasome. Direct targeting of NLRP3 protein can be a better choice because it can prevent off target immunosuppressive effects, thus restrain tissue destruction. This paper will review the various pharmacological inhibitors of the NLRP3 inflammasome and will also discuss their mechanism of action.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.02538

Cites

0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic illustration of NLRP3 inflammasome pathway and potential blockade sites of various pharmacological inhibitors. The signal 1 or the priming signal is mediated by pathogenic PAMPs from bacteria or virus, or sterile DAMPs resulting in NF-κB-dependent upregulation of NLRP3 and pro-IL-1β expression. The signal 2 or activation signal mediated by numerous PAMP or DAMP stimulation, promotes the NLRP3 oligomerization, and recruitment of ASC and pro-caspase-1, leading to the activation of NLRP3 inflammasome complex. NLRP3 can be activated in response to extracellular ATP and K+ efflux through the ATP-gated P2X7 channel, in response to cathepsin B release from damaged lysosomes or in response to reactive oxygen species (ROS) released from damaged mitochondria. NLRP3 inflammasome activation results in active caspase-1, which cleaves the proforms of IL-1β and IL-18 into their mature forms. ASC, apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain; ATP, adenosine triphosphate; BHB, β-Hydroxybutyrate; CARD, caspase recruitment domain; DAMPS, danger or damage associated molecular patterns; IL, interleukin; LRR, leucine-rich repeat; MNS, methylenedioxy-β-nitrostyrene; NACHT, central nucleotide-binding and oligomerization; NF-κB, nuclear factor kappa B; Ori, oridonin; P2X7, P2X purinergic receptor 7; PAMPS, pathogen associated molecular patterns; PYD, pyrin domain; ROS, reactive oxygen species; TLR, toll-like receptor; TR, tranilast.
Figure 1 Schematic illustration of NLRP3 inflammasome pathway and potential blockade sites of various pharmacological inhibitors. The signal 1 or the priming signal is mediated by pathogenic PAMPs from bacteria or virus, or sterile DAMPs resulting in NF-κB-dependent upregulation of NLRP3 and pro-IL-1β expression. The signal 2 or activation signal mediated by numerous PAMP or DAMP stimulation, promotes the NLRP3 oligomerization, and recruitment of ASC and pro-caspase-1, leading to the activation of NLRP3 inflammasome complex. NLRP3 can be activated in response to extracellular ATP and K+ efflux through the ATP-gated P2X7 channel, in response to cathepsin B release from damaged lysosomes or in response to reactive oxygen species (ROS) released from damaged mitochondria. NLRP3 inflammasome activation results in active caspase-1, which cleaves the proforms of IL-1β and IL-18 into their mature forms. ASC, apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain; ATP, adenosine triphosphate; BHB, β-Hydroxybutyrate; CARD, caspase recruitment domain; DAMPS, danger or damage associated molecular patterns; IL, interleukin; LRR, leucine-rich repeat; MNS, methylenedioxy-β-nitrostyrene; NACHT, central nucleotide-binding and oligomerization; NF-κB, nuclear factor kappa B; Ori, oridonin; P2X7, P2X purinergic receptor 7; PAMPS, pathogen associated molecular patterns; PYD, pyrin domain; ROS, reactive oxygen species; TLR, toll-like receptor; TR, tranilast.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 107

  1. Neill, 2010, Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity, Nature, 464, 1367, 10.1038/nature08900 · DOI
  2. Fullard, 2015, Role of innate immune system in systemic sclerosis, Semin Immunopathol., 37, 511, 10.1007/s00281-015-0503-7 · DOI
  3. Martinon, 2002, The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β, Mol Cell., 10, 417, 10.1016/S1097-2765(02)00599-3 · DOI · Paper page
  4. Sanders, 2015, Single-cell imaging of inflammatory caspase dimerization reveals differential recruitment to inflammasomes, Cell Death Dis, 6, e1813, 10.1038/cddis.2015.186 · DOI
  5. Schroder, 2010, The inflammasomes, Cell., 140, 821, 10.1016/j.cell.2010.01.040 · DOI · Paper page
  6. Minkiewicz, 2013, Human astrocytes express a novel NLRP2 inflammasome, Glia, 61, 1113, 10.1002/glia.22499 · DOI
  7. Inoue, 2013, The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis–in the perspective of inflammasomes, Immunology, 139, 11, 10.1111/imm.12081 · DOI
  8. Ito, 2015, Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury, Nat Commun, 6, 7360, 10.1038/ncomms8360 · DOI
  9. Inoue, 2013, Nlrp3 inflammasome and MS/EAE, Autoimmune Dis., 2013, 859145, 10.1155/2013/859145 · DOI
  10. Zhong, 2013, Functions of NOD-like receptors in human diseases, Front Immunol, 4, 333, 10.3389/fimmu.2013.00333 · DOI
  11. Duncan, 2007, Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling, Proc Natl Acad Sci USA., 104, 8041, 10.1073/pnas.0611496104 · DOI
  12. Sharif, 2019, Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome, Nature, 570, 338, 10.1038/s41586-019-1295-z · DOI · Paper page
  13. Franchi, 2012, Sensing and reacting to microbes through the inflammasomes, Nat Immunol., 13, 325, 10.1038/ni.2231 · DOI
  14. Doyle, 2012, NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components, Nat Med., 18, 791, 10.1038/nm.2717 · DOI
  15. Martín-Sánchez, 2016, Inflammasome-dependent IL-1β release depends upon membrane permeabilisation, Cell Death Different, 23, 1219, 10.1038/cdd.2015.176 · DOI
  16. Gaidt, 2018, The NLRP3 inflammasome renders cell death pro-inflammatory, J Mol Biol, 430, 133, 10.1016/j.jmb.2017.11.013 · DOI · Paper page
  17. Mangan, 2018, Targeting the NLRP3 inflammasome in inflammatory diseases, Nat Rev Drug Discov, 17, 588, 10.1038/nrd.2018.97 · DOI · Paper page
  18. Bauernfeind, 2009, Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression, J Immunol, 183, 787, 10.4049/jimmunol.0901363 · DOI
  19. Franchi, 2014, Cytosolic double-stranded RNA activates the NLRP3 inflammasome via MAVS-induced membrane permeabilization and K+ efflux, J Immunol, 193, 4214, 10.4049/jimmunol.1400582 · DOI
  20. Juliana, 2012, Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation, J Biol Chem, 287, 36617, 10.1074/jbc.M112.407130 · DOI
  21. Ghonime, 2014, Inflammasome priming by LPS is dependent upon ERK signaling and proteasome function, J Immunol, 192, 3881, 10.4049/jimmunol.1301974 · DOI
  22. Py, 2013, Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity, Mol Cell, 49, 331, 10.1016/j.molcel.2012.11.009 · DOI
  23. Kim, 2015, Increased expression of the NLRP3 inflammasome components in patients with Behçet's disease, 12, 41, 10.1186/s12950-015-0086-z · DOI
  24. Ozaki, 2015, Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives, J Inflamm Res, 8, 15, 10.2147/JIR.S51250 · DOI
  25. Heid, 2013, Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation, J Immunol., 191, 5230, 10.4049/jimmunol.1301490 · DOI
  26. Perregaux, 1994, Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity, J Biol Chem., 269, 15195, 10.1016/S0021-9258(17)36591-2 · DOI
  27. Okada, 2014, The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation, J Biol Chem, 289, 32926, 10.1074/jbc.M114.579961 · DOI
  28. Lee, 2013, Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes, Diabetes, 62, 194, 10.2337/db12-0420 · DOI
  29. Altaf, 2015, NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins, Coron Artery Dis, 26, 409, 10.1097/MCA.0000000000000255 · DOI
  30. Patel, 2015, Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation, Proc Natl Acad Sci USA, 112, 506, 10.1073/pnas.1414536112 · DOI
  31. Peng, 2015, P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation, Int J Mol Med., 35, 1179, 10.3892/ijmm.2015.2129 · DOI
  32. Shao, 2014, Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP 3 inflammasome, CNS Neurosci Ther, 20, 1021, 10.1111/cns.12349 · DOI
  33. Inoue, 2012, NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis, Proc Natl Acad Sci USA, 109, 10480, 10.1073/pnas.1201836109 · DOI
  34. Cheng, 2015, Effect of enterohaemorrhagic Escherichia coli O 157: H 7-specific enterohaemolysin on interleukin-1β production differs between human and mouse macrophages due to the different sensitivity of NLRP 3 activation, Immunology, 145, 258, 10.1111/imm.12442 · DOI
  35. Guo, 2015, Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation, Int Immunopharmacol, 24, 232, 10.1016/j.intimp.2014.12.009 · DOI
  36. Sun, 2015, Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation, Biochem pharmacol, 94, 142, 10.1016/j.bcp.2015.02.002 · DOI
  37. Kolb, 2014, Inflammasomes in cancer: a double-edged sword, Protein Cell., 5, 12, 10.1007/s13238-013-0001-4 · DOI
  38. Karki, Inflammasomes and cancer, Cancer Immunol Res, 5, 94, 10.1158/2326-6066.CIR-16-0269 · DOI
  39. Ozkurede, 2012, Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes, Clin Exp Immunol, 167, 382, 10.1111/j.1365-2249.2011.04535.x · DOI
  40. Hu, 2014, Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism, PLoS ONE., 9, e85765, 10.1371/journal.pone.0085765 · DOI
  41. Liu, 2014, TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury, Basic Res Cardiol, 109, 415, 10.1007/s00395-014-0415-z · DOI
  42. Jiang, 2017, Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders, J Exp Med, 214, 3219, 10.1084/jem.20171419 · DOI
  43. He, 2014, 3, 4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome, J Biol Chem, 289, 1142, 10.1074/jbc.M113.515080 · DOI
  44. Perregaux, 2001, Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors, J Pharmacol Exp Ther, 299, 187
  45. Marchetti, 2015, Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and non-ischemic injury in the mouse, J Cardiovasc Pharmacol, 66, 1, 10.1097/FJC.0000000000000247 · DOI
  46. Marchetti, 2014, A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury following ischemia-reperfusion in the mouse, J Cardiovasc Pharmacol, 63, 316, 10.1097/FJC.0000000000000053 · DOI
  47. Kuwar, 2019, A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury, J Neuroinflamm., 16, 81, 10.1186/s12974-019-1471-y · DOI
  48. Liu, 2013, A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome, Biochem Pharmacol, 85, 1504, 10.1016/j.bcp.2013.03.008 · DOI
  49. Juliana, 2010, Anti-inflammatory compounds parthenolide and Bay 11–7082 are direct inhibitors of the inflammasome, J Biol Chem, 285, 9792, 10.1074/jbc.M109.082305 · DOI
  50. Saadane, 2007, Parthenolide inhibits IκB Kinase, NF-κB activation, and inflammatory response in cystic fibrosis cells and mice, Am J Respir Cell Mol Biol, 36, 728, 10.1165/rcmb.2006-0323OC · DOI
  51. Boxer, 2010, A Small Molecule Inhibitor of Caspase 1
  52. Rudolphi, 2003, Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis, Osteoarthritis Cartilage, 11, 738, 10.1016/S1063-4584(03)00153-5 · DOI
  53. Wannamaker, 2007, (S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhi, J Pharmacol Exp Ther, 321, 509, 10.1124/jpet.106.111344 · DOI · Paper page
  54. Strickson, 2013, The anti-inflammatory drug BAY 11–7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system, Biochem J, 451, 427, 10.1042/BJ20121651 · DOI
  55. Meng, 2010, IKK inhibitor bay 11-7082 induces necroptotic cell death in precursor-B acute lymphoblastic leukaemic blasts, Br J Haematol, 148, 487, 10.1111/j.1365-2141.2009.07988.x · DOI
  56. Krishnan, 2013, The anti-inflammatory compound BAY 11–7082 is a potent inhibitor of Protein Tyrosine Phosphatases, FEBS J, 280, 2830, 10.1111/febs.12283 · DOI
  57. Coll, 2019, MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition, Nat Chem Biol, 15, 556, 10.1038/s41589-019-0277-7 · DOI
  58. Huang, 2018, Tranilast directly targets NLRP3 to treat inflammasome-driven diseases, EMBO Mol Med, 10, e8689, 10.15252/emmm.201708689 · DOI
  59. Marchetti, 2018, OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation, Proc Natl Acad Sci USA, 115, E1530, 10.1073/pnas.1716095115 · DOI
  60. He, 2018, Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity, Nat Commun, 9, 2550, 10.1038/s41467-018-04947-6 · DOI · Paper page
  61. Riddle, 2003, Editorial: sulfonylureas differ in effects on ischemic preconditioning–is it time to retire glyburide?, J Clin Endocrinol Metab, 88, 528, 10.1210/jc.2002-021971 · DOI
  62. Ashcroft, 2005, ATP-sensitive potassium channelopathies: focus on insulin secretion, J Clin Invest, 115, 2047, 10.1172/JCI25495 · DOI
  63. Mariathasan, 2004, Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf, Nature., 430, 213, 10.1038/nature02664 · DOI
  64. Hamon, 1997, Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1, Blood, 90, 2911, 10.1182/blood.V90.8.2911 · DOI
  65. Lottaz, 2001, Inhibition of ATP-binding cassette transporter downregulates interleukin-1beta-mediated autocrine activation of human dermal fibroblasts, J Invest Dermatol., 117, 871, 10.1046/j.0022-202x.2001.01451.x · DOI
  66. Fulp, 2018, Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization, J Med Chem., 61, 5412, 10.1021/acs.jmedchem.8b00733 · DOI
  67. Yin, 2018, NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer's disease, Mol Neurobiol, 55, 1977, 10.1007/s12035-017-0467-9 · DOI
  68. Heinrich, 1998, Ethnopharmacology of Mexican asteraceae (compositae), Ann Rev Pharmacol Toxicol, 38, 539, 10.1146/annurev.pharmtox.38.1.539 · DOI
  69. Guzman, 2007, An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells, Blood., 110, 4427, 10.1182/blood-2007-05-090621 · DOI
  70. D'anneo, 2013, Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer, Cell Death Dis., 4, e891, 10.1038/cddis.2013.415 · DOI
  71. Mackenzie, 2010, The potential for caspases in drug discovery, Curr Opin Drug Discov Devel, 13, 568, 10.4049/jimmunol.168.6.3024 · DOI
  72. Siegmund, 2003, Pralnacasan (vertex pharmaceuticals), IDrugs, 6, 154
  73. Strand, 2009, Randomized controlled trial design in rheumatoid arthritis: the past decade, Arthritis Res Ther, 11, 205, 10.1186/ar2555 · DOI
  74. Fischer, 2005, Apoptosis-based therapies and drug targets, Cell Death Different, 12, 942, 10.1038/sj.cdd.4401556 · DOI
  75. Maroso, 2011, Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1, J Int Med, 270, 319, 10.1111/j.1365-2796.2011.02431.x · DOI · Paper page
  76. Flores, 2018, Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model, Nat Commun, 9, 3916, 10.1038/s41467-018-06449-x · DOI
  77. Audia, 2018, Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function, Basic Res Cardiol., 113, 32, 10.1007/s00395-018-0692-z · DOI
  78. Kerr, 2009, Vinyl sulfones as antiparasitic agents and a structural basis for drug design, J Biol Chem, 284, 25697, 10.1074/jbc.M109.014340 · DOI
  79. Daniels, 2016, Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models, Nat Commun, 7, 12504, 10.1038/ncomms12504 · DOI
  80. Dempsey, 2017, Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice, Brain Behav Immun, 61, 306, 10.1016/j.bbi.2016.12.014 · DOI · Paper page
  81. Vande Walle, 2019, MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition, bioRxiv, 634493, 10.1101/634493 · DOI
  82. Primiano, 2016, Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation, J Immunol, 197, 2421, 10.4049/jimmunol.1600035 · DOI
  83. Ma, 2002, Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin–induced intestinal fluid secretion, J Clin Invest, 110, 1651, 10.1172/JCI16112 · DOI
  84. Sonawane, 2008, Thiazolidinone CFTR inhibitors with improved water solubility identified by structure–activity analysis, Bioorgan Med Chem, 16, 8187, 10.1016/j.bmc.2008.07.044 · DOI
  85. Darakhshan, 2015, Tranilast: a review of its therapeutic applications, Pharmacol Res, 91, 15, 10.1016/j.phrs.2014.10.009 · DOI
  86. Konneh, 1998, Tranilast Kissei pharmaceutical, IDrugs, 1, 141
  87. Platten, 2005, Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite, Science, 310, 850, 10.1126/science.1117634 · DOI
  88. Toldo, 2018, The NLRP3 inflammasome in acute myocardial infarction, Nat Rev Cardiol, 15, 203, 10.1038/nrcardio.2017.161 · DOI
  89. Kadota, 1997, Antibacterial activity of trichorabdal A from Rabdosia trichocarpa against Helicobacter pylori, Zentralblatt Bakteriol, 286, 63, 10.1016/S0934-8840(97)80076-X · DOI
  90. Kuo, 2014, Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells, Molecules, 19, 3327, 10.3390/molecules19033327 · DOI
  91. Ding, 2016, Discovery and development of natural product oridonin-inspired anticancer agents, Eur J Med Chem, 122, 102, 10.1016/j.ejmech.2016.06.015 · DOI
  92. Fujita, 1976, The antitumor and antibacterial activity of the Isodon diterpenoids, Chem Pharm Bull, 24, 2118, 10.1248/cpb.24.2118 · DOI
  93. Huang, 2005, A comparison of the signal pathways between the TNFα-and oridonin-induced Murine L929 fibrosarcoma cell death, Acta Med Okayama, 59, 261, 10.18926/AMO/31960 · DOI
  94. Xu, 2009, Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia, Int Immunopharmacol, 9, 360, 10.1016/j.intimp.2009.01.002 · DOI
  95. Zhao, 2017, Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264. 7 cells and acute lung injury, Oncotarget, 8, 68153, 10.18632/oncotarget.19249 · DOI
  96. Wang, 2015, Oridonin's therapeutic effect: Suppressing T h1/T h17 simultaneously in a mouse model of C rohn's disease, J Gastroenterol Hepatol, 30, 504, 10.1111/jgh.12710 · DOI
  97. Wang, 2014, Oridonin attenuates Aβ1–42-induced neuroinflammation and inhibits NF-κB pathway, PLoS ONE, 9, e104745, 10.1371/journal.pone.0104745 · DOI
  98. Zhang, 2013, Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis, J Cell Mol Med, 17, 1566, 10.1111/jcmm.12124 · DOI
  99. Jiang, 2018, The NLRP3 inflammasome: role in metabolic disorders and regulation by metabolic pathways, Cancer Lett, 419, 8, 10.1016/j.canlet.2018.01.034 · DOI
  100. Dinarello, 2013, Treating inflammation by blocking interleukin-1 in humans, Semin Immunol., 25, 469, 10.1016/j.smim.2013.10.008 · DOI
  101. Nowarski, 2015, Epithelial IL-18 equilibrium controls barrier function in colitis, Cell, 163, 1444, 10.1016/j.cell.2015.10.072 · DOI
  102. Lu, 2012, Novel role of PKR in inflammasome activation and HMGB1 release, Nature, 488, 670, 10.1038/nature11290 · DOI
  103. Kanneganti, 2018, GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever, 215, 1519, 10.1084/jem.20172060 · DOI
  104. Xiao, 2018, Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice, PLoS Biol, 16, e3000047, 10.1371/journal.pbio.3000047 · DOI
  105. Gaidt, 2016, Pore formation by GSDMD is the effector mechanism of pyroptosis, EMBO J, 35, 2167, 10.15252/embj.201695415 · DOI
  106. Salvador, 2019, Nanobody: outstanding features for diagnostic and therapeutic applications, Anal Bioanal Chem, 411, 1703, 10.1007/s00216-019-01633-4 · DOI
  107. Konning, 2017, Camelid and shark single domain antibodies: structural features and therapeutic potential, Curr Opin Struct Biol, 45, 10, 10.1016/j.sbi.2016.10.019 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J.
Affiliations
University of Science and Technology of China (CN)
Corresponding author
Jin, Tengchuan
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2019-10-25
Volume
10
Pages
2538-2538
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2019.02538
PMC
PMC6842943
OpenAlex
W2982061867
Cited by
671
References
123
Citations by year
2026: 49 · 2025: 94 · 2024: 107 · 2023: 101 · 2022: 129 · 2021: 122 · 2020: 69
FWCI
7.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (201904a07020103, 81771774)
  • Natural Science Foundation of Anhui Province (1708085MH191)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords
NLRP3 inflammasome, inflammasome inhibitors, NLRP3, ASC, pyroptosis, inflammatory cytokines, innate immunity, diabetes mellitus, atherosclerosis, metabolic syndrome, neurodegenerative diseases, cardiovascular disease, mechanism of action
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Dipeptides, Glyburide, Humans, Nitriles, Sulfones, Inflammasomes, para-Aminobenzoates, ortho-Aminobenzoates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review